Revolutionizing HIV-1 Viral Load Monitoring in India: The Potential of Dried Blood Spot Analysis for Expanding Access and Improving Care
Chandane Tak et al.
The finding, in our words
The review found dried blood spot sampling correlates strongly with plasma for HIV-1 viral load and offers simplified collection, transport and storage without cold-chain. This could expand access to monitoring in resource-limited settings and improve clinical outcomes through earlier detection of treatment failure.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
The study validated a semi-quantitative protocol for Epstein-Barr virus serology using dried blood spots, demonstrating 98.8% sensitivity and 96.5% specificity compared to paired venous serum samples. The successful validation in a self-sampling cohort confirms the suitability of this patient-centric microsampling approach for large-scale seroprevalence studies and decentralised trials.
Capillary samples collected using dried blood spots and Mitra microsamplers showed strong agreement with venous plasma for quantifying IgG antibodies against most vaccine-preventable diseases. Sensitivity was high for the majority of pathogens, though the study noted that antibody stability declined at room temperature over time, favouring cold storage for longer durations.
Self-collected dried blood spots analysed on the Roche Elecsys platform gave quantitative anti-spike antibody results that agreed closely with paired venous samples, with sensitivity 96.63% and specificity 97.81% and a conversion formula across 0.018 to 250 U/mL, enabling accurate tracking of titre changes in longitudinal cohorts after vaccination.
Dried blood spot eluates showed high agreement with serum for SARS-CoV-2 IgG against Spike and Nucleocapsid (r≈0.96; qualitative φ≈0.98–1.0) and remained stable after 6–8 hours of storage, supporting use of capillary DBS for serosurveys and decentralised testing.
In 1070 young adults, dried blood spot eluates correlated strongly with serum for anti-spike IgGAM and total IgG, IgA and IgM; labDBS achieved 82.0% sensitivity and 98.2% specificity and ssDBS 86.1% sensitivity and 96.7% specificity versus serum, with minimal difference between self and investigator collection.